“We have never had more data, and never had less of it read.”
Allan started paying attention in 2018, watching the science expand faster than the law around it and wondering whether the trials, the statutes and the money would follow the shape cannabis had already traced. Almost none of it was written down anywhere a reader could check a claim against. The database dates to 2019, started while the industry around it was still forming, and after several starts and stops The Psilocybin Record launched in 2026.
The pieces start in the register. Some are a question the data answers outright; more are a matter of reading what sits scattered across the filings and setting it down in one place. Allan reports what the documents show and leaves the arguing to other people. Every figure arrives with the denominator it came from, and every claim names the statute, the registration or the release it rests on. When the answer is that nobody has published the number, that is the piece.
Topics covered
- Prescribing and access routes
- Clinical trials and their sponsors
- Scheduling decisions
- Legislation
Analysis
- A psychiatrist in Australia can prescribe psilocybin, for exactly one condition.Since 1 July 2023 a specialist psychiatrist in Australia can prescribe psilocybin for treatment-resistant depression, and for nothing else.
- The access route the psychedelics executive order named does not existExecutive Order 14401 directed the FDA and the Drug Enforcement Administration to establish a way for eligible patients to get psychedelic drugs under the Right to Try Act.
- Who makes the psilocybin in a clinical trial?In roughly 8% of registered psilocybin trials, the name on the drug isn’t the sponsor’s. No index built on sponsors can show that, and ours is one of them.
Analysis argues from the register and is labelled as analysis. It never writes back into an entry.